India’s pharmaceutical exports grew 6.8% year-on-year to reach ₹0.772 lakh crore (US$ 8.10 billion) during Q1 FY27, up from ₹0.723 lakh crore (US$ 8.18 billion) in Q1 FY26, according to data from Pharmexcil. Growth was primarily driven by drug formulations and biological products, which generated US$ 5.98 billion—representing 73.85% of total exports—and grew by 4.14%. Among other categories, bulk drugs and intermediates rose 13.84% to US$ 1.36 billion, while vaccine exports registered a sharp 35.68% surge to US$ 0.39 billion. Surgical products also grew by 11.95%, reaching US$ 0.21 billion during the quarter. Key global markets remained strongly reliant on Indian supplies, with NAFTA, Europe, Africa, and Latin America & the Caribbean together accounting for nearly 75% of total exports. NAFTA represented the largest regional share at 34.28%, with the United States standing as the single largest destination at US$ 2.50 billion, followed by Brazil, the UK, the Netherlands, and France. Altogether, the top 25 export destinations accounted for nearly 70% of total shipments, valued at ₹0.539 lakh crore (US$ 5.65 billion). This sustained momentum underscores expanding capabilities across the value chain, backed by investments in advanced manufacturing, regulatory compliance, and high-value formulations. $SUNPHARMA

#FundamentalViews#StockInNews#MacroViews#Miscellaneous#TrendingSectors

708 likes·61 comments